Wednesday, May 21, 2025 IND.232, a Phase II Study of Durvalumab (MEDI4736) with or without tremelimumab in patients with metastatic castration resistant prostate cancer, has permanently closed.The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer. In addition, this study looked at the side effects of durvalumab when given alone or in combination with tremelimumab. Programmed death-ligand 1 (PD-L1) is overexpressed by dendritic cells in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on androgen receptor pathway inhibitors. Testing whether checkpoint blockade could enhance antitumor activity in mCRPC. D+T is active in mCRPC but patient selection remains a challenge. Further studies to develop predictive biomarkers are warranted. For more information please visit the IND232 Trial Page.Clinicaltrials.gov Results Reporting: NCT02788773
